FORT WORTH, TX – Alcon, a division of Novartis, has acquired Tear Film Innovations Inc., a privately held company and manufacturer of the iLux Device used to treat meibomian gland dysfunction, a leading cause of dry eye.
Financial terms of the deal were not disclosed.
The acquisition expands Alcon’s portfolio of ocular health products, including several treatments for the temporary relief of dry eye symptoms.
Using the iLux, a practitioner can warm the eyelids via disposable silicone pads to address blocked meibomian glands through the application of light-based heating.
“With the acquisition of Tear Film, we’re excited to bring this latest innovation to treat the millions of people around the world who suffer from dry eye,” said Andy Pawson, Alcon president and general manager, Global Vision Care Franchise. “Alcon remains committed to improving the lives of patients around the world through innovative technologies like the iLux Device to address significant unmet needs in eye care.”
The device received 510(k) clearance from the U.S. Food and Drug Administration in December 2017 and was officially launched by Tear Film in May 2018 at the annual meeting of the American Society for Cataract and Refractive Surgery.
The iLux is available in the U.S. and Canada. Alcon expects to announce plans to expand to other countries in 2019.
“Since launching the iLux Device earlier this year, we’ve seen an enthusiastic response from eye care professionals who have already begun to incorporate it as an advanced treatment option for patients suffering from Meibomian Gland Dysfunction,” said Rob Thornhill, CEO of Tear Film. “Now, as part of Alcon, we’re eager to bring this technology to even more offices throughout the world.”